Delivery Order 75N95023D00019-75N95024F00001
Award Date
9/12/24
Potential Completion Date
3/11/26
Potential Value
$1.4M
Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Overland Park, KS 66212, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $3,562,513 cost-plus-fixed-fee definitive contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to Altasciences Clinical Kansas Inc. The contract is for pharmacokinetic and pharmacodynamic studies to support the development of medications for substance use disorders. The contract period of performance is from September 20, 2017 to September 19, 2022, with an ultimate completion date of July 31, 2025. This award is not associated...
This is a firm fixed price delivery order awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to Altasciences Clinical Kansas Inc., a contract research organization. The $1,838,615.00 delivery order is for Altasciences to conduct Phase 1 cocaine drug interaction trials from September 2023 through March 2025 in Overland Park, Kansas. This delivery order was issued against an existing $21 million single-award indefinite delivery contract with NIDA for...
This federal contract award, with a ceiling value of $1,927,163.66, was issued by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services. The contract was awarded to SRI International, a non-profit research and development organization, and is part of NIDA's Pharmacology and Toxicology for Neurotherapeutics Program (PTNP). The contract, which is a Delivery Order under the PTNP Indefinite Delivery Vehicle (IDV), is for IND-enabling studies....
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $1.46 million firm fixed price delivery order to Medical Science & Computing, LLC. This Task Order #11 was issued against the Scientific, Operations, and Administrative Resources to the National Institutes of Health indefinite-delivery/indefinite-quantity master contract vehicle to provide unspecified services in support of NIH programs in Bethesda, Maryland, over a...
This federal contract award is for the evaluation of a potential respiratory stimulant on behalf of the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH). The award, with a ceiling value of $140,848.00, was issued to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The scope of work includes nonclinical animal studies to assess potential treatments for drug-induced respiratory depression and...
The National Institute on Drug Abuse has awarded a $1,804,120 cost-plus-fixed-fee delivery order to The Emmes Company LLC under an indefinite delivery contract vehicle. This task order provides management and support services for NIDA's Data, Statistics, and Clinical Trial Support Center from February 29, 2024 through February 28, 2025. No set-aside designation was used for this award. The Emmes Company will deliver data coordinating, statistical analysis, and logistical support for NIDA's...
This federal contract award was made by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $101,372.00 firm fixed-price delivery order contract is part of the NIH Bioanalysis Testing Services 2015-2020 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. Under this award, Pharmaron will provide a range of preclinical research services to support NIDA's drug discovery and development initiatives,...
The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $382,010.00 Firm Fixed Price Delivery Order contract to Vitae Enim Vitae Scientific, Inc. (VEV Scientific) on September 27, 2024. The contract is for dosage form reprocessing and stability studies of the FX-5A injection drug product under an Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Chemistry, Manufacturing and Controls (CMC) and related services to support drug product development. The contract...
<p>The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $24,900 firm fixed price purchase order contract to Pelago Bioscience AB, a for-profit limited liability company. The contract is for the development of a new assay to test compounds of interest. The period of performance runs from the award date of September 9, 2024 through September 8, 2025. This contract award does not have a set-aside designation.</p>
This is a delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian federal agency, to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, and Hispanic American-owned small business. The $415,717.00 contract is for a Phase I Single Ascending Dose Study under NIDA's Pharmacokinetic Analysis Resource Center program. The work will be performed in Westlake, Maryland from September 10, 2024 to March 9, 2026. This contract is not set aside and is a...